Literature DB >> 18391206

Hybrid alphavirus-rhabdovirus propagating replicon particles are versatile and potent vaccine vectors.

Nina F Rose1, Jean Publicover, Anasuya Chattopadhyay, John K Rose.   

Abstract

Self-propagating, infectious, virus-like particles are generated in animal cell lines transfected with a Semliki Forest virus RNA replicon encoding a single viral structural protein, the vesicular stomatitis virus (VSV) glycoprotein. We show here that these infectious particles, which we call propagating replicons, are potent inducers of neutralizing antibody in animals yet are nonpathogenic. Mice vaccinated with a single dose of the particles generated high titers of VSV-neutralizing antibody and were protected from a subsequent lethal challenge with VSV. Induction of antibody required RNA replication. We also report that additional genes (including an HIV-1 envelope protein gene) expressed from the propagating replicons induced strong cellular immune responses to the corresponding proteins after a single inoculation. Our studies reveal the potential of these particles as simple and safe vaccine vectors inducing strong humoral and cellular immune responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18391206      PMCID: PMC2311333          DOI: 10.1073/pnas.0800280105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  Preferential localization of effector memory cells in nonlymphoid tissue.

Authors:  D Masopust; V Vezys; A L Marzo; L Lefrançois
Journal:  Science       Date:  2001-03-01       Impact factor: 47.728

2.  The glycoprotein of vesicular stomatitis virus is the antigen that gives rise to and reacts with neutralizing antibody.

Authors:  J M Kelley; S U Emerson; R R Wagner
Journal:  J Virol       Date:  1972-12       Impact factor: 5.103

3.  Cytoplasmic structures associated with an arbovirus infection: loci of viral ribonucleic acid synthesis.

Authors:  P M Grimley; I K Berezesky; R M Friedman
Journal:  J Virol       Date:  1968-11       Impact factor: 5.103

4.  The interactionof antiody with the major surface glycoprotein of vesicular stomatitis virus. I. Analysis of neutralizing epitopes with monoclonal antibodies.

Authors:  L Lefrancios; D S Lyles
Journal:  Virology       Date:  1982-08       Impact factor: 3.616

5.  High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses.

Authors:  Karl Haglund; Ingrid Leiner; Kristen Kerksiek; Linda Buonocore; Eric Pamer; John K Rose
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

6.  Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1.

Authors:  N F Rose; A Roberts; L Buonocore; J K Rose
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

7.  A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector.

Authors:  Jean Publicover; Elizabeth Ramsburg; John K Rose
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

8.  Delivery and expression of heterologous genes in mammalian cells using self-replicating alphavirus vectors.

Authors:  Gunilla B Karlsson; Peter Liljeström
Journal:  Methods Mol Biol       Date:  2004

9.  Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses.

Authors:  Jean Publicover; Elizabeth Ramsburg; John K Rose
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Cell surface expression of fusogenic vesicular stomatitis virus G protein from cloned cDNA.

Authors:  H Riedel; C Kondor-Koch; H Garoff
Journal:  EMBO J       Date:  1984-07       Impact factor: 11.598

View more
  16 in total

1.  Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen.

Authors:  John B Schell; Nina F Rose; Kapil Bahl; Kathryn Diller; Linda Buonocore; Meredith Hunter; Preston A Marx; Ratish Gambhira; Haili Tang; David C Montefiori; Welkin E Johnson; John K Rose
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

2.  Rescue of infectious particles from preassembled alphavirus nucleocapsid cores.

Authors:  Jonathan E Snyder; Odisse Azizgolshani; Bingbing Wu; Yingpei He; Aih Cheun Lee; Joyce Jose; Daniel M Suter; Charles M Knobler; William M Gelbart; Richard J Kuhn
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

3.  In vitro evolution of high-titer, virus-like vesicles containing a single structural protein.

Authors:  Nina F Rose; Linda Buonocore; John B Schell; Anasuya Chattopadhyay; Kapil Bahl; Xinran Liu; John K Rose
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-10       Impact factor: 11.205

4.  Pseudo-typed Semliki Forest virus delivers EGFP into neurons.

Authors:  Fan Jia; Huan Miao; Xutao Zhu; Fuqiang Xu
Journal:  J Neurovirol       Date:  2016-10-13       Impact factor: 2.643

5.  Heterologous prime-boost immunization with vesiculovirus-based vectors expressing HBV Core antigen induces CD8+ T cell responses in naïve and persistently infected mice and protects from challenge.

Authors:  Carolina Chiale; Safiehkhatoon Moshkani; John K Rose; Michael D Robek
Journal:  Antiviral Res       Date:  2019-05-30       Impact factor: 5.970

6.  Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain.

Authors:  Anthony N van den Pol; Guochao Mao; Anasuya Chattopadhyay; John K Rose; John N Davis
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

7.  Mechanisms of Innate Immune Activation by a Hybrid Alphavirus-Rhabdovirus Vaccine Platform.

Authors:  Anthony M Marchese; Carolina Chiale; Safiehkhatoon Moshkani; Michael D Robek
Journal:  J Interferon Cytokine Res       Date:  2019-10-18       Impact factor: 2.607

8.  Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: a New Approach for a CHIKV Vaccine.

Authors:  Ya-Nan Zhang; Cheng-Lin Deng; Jia-Qi Li; Na Li; Qiu-Yan Zhang; Han-Qing Ye; Zhi-Ming Yuan; Bo Zhang
Journal:  J Virol       Date:  2019-07-17       Impact factor: 5.103

Review 9.  Development of replication-competent viral vectors for HIV vaccine delivery.

Authors:  Christopher L Parks; Louis J Picker; C Richter King
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

10.  Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.

Authors:  Tracy D Reynolds; Linda Buonocore; Nina F Rose; John K Rose; Michael D Robek
Journal:  J Virol       Date:  2015-08-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.